

United States Patent and Trademark Office

010

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/720,136	03/16/2001	Beverly B. Teter	UMARY3	7554	
23599	23599 7590 11/10/2005			EXAMINER	
MILLEN, WHITE, ZELANO & BRANIGAN, P.C. 2200 CLARENDON BLVD.			WEDDINGTON, KEVIN E		
			ART UNIT	PAPER NUMBER	
SUITE 1400 ARLINGTON	, VA 22201		1614		

DATE MAILED: 11/10/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)		
Office Action Summary		09/720,136	TETER, BEVERLY B.		
		Examiner	Art Unit		
		Kevin E. Weddington	1614		
 Period for	The MAILING DATE of this communication app Reply	ears on the cover sheet with the c	orrespondence address		
A SHO WHICH - Extensi after SI - If NO p - Failure Any rep	RTENED STATUTORY PERIOD FOR REPLY IEVER IS LONGER, FROM THE MAILING DA ons of time may be available under the provisions of 37 CFR 1.13 X (6) MONTHS from the mailing date of this communication. eriod for reply is specified above, the maximum statutory period w to reply within the set or extended period for reply will, by statute, ly received by the Office later than three months after the mailing patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	I. lely filed the mailing date of this communication. (35 U.S.C. § 133).		
Status					
1)⊠ F	Responsive to communication(s) filed on 30 De	<u>ecember 2004</u> .			
/	This action is FINAL . 2b)⊠ This action is non-final.				
,—	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
	·	x parte Quayle, 1955 C.D. 11, 45			
Dispositio	n of Claims				
5)□ C 6)図 C 7)□ C	Claim(s) 10-18,25,26,38,45 and 51 is/are pend a) Of the above claim(s) is/are withdray claim(s) is/are allowed. Claim(s) 10-18,25,26,38,45 and 51 is/are reject claim(s) is/are objected to. Claim(s) are subject to restriction and/or	vn from consideration.			
Applicatio	n Papers				
10)□ TI A F	he specification is objected to by the Examine the drawing(s) filed on is/are: a) access applicant may not request that any objection to the detection declaration is objected to by the Examine specific part of the coath or declaration is objected to by the Examine specific part of the specific pa	epted or b) objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).		
Priority un	der 35 U.S.C. § 119				
a)	cknowledgment is made of a claim for foreign All b)	s have been received. s have been received in Application ity documents have been receive i (PCT Rule 17.2(a)).	on No ed in this National Stage		
Attachment(s			(PTO 442)		
2) Notice 3) Informa	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:			

Claims 10-18, 25, 26, 38, 45 and 51 are presented for examination.

Applicant's amendment filed December 30, 2004 has been received and entered.

Accordingly, the rejections made in the Office action dated September 27, 2004 is vacated so that a new Office action can be made.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 14 and 51 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 14 recites the limitation "at least one antibiotic" in claim 2 and claim 51 recites the limitation "as in claim 10, wherein the antibiotic is" in lines 1 and 2. But claim 10 does not disclose the use of other antibiotics in the composition.

There is insufficient antecedent basis for this limitation in the claim.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Art Unit: 1614

Claims 10-12, 18, 38 and 45 rejected under 35 U.S.C. 103(a) as being unpatentable over Ohzeki et al. (4,569,846) in view of Isaacs et al. (5,434,182).

Ohzeki et al. teach a composition comprising a crude protein product and an oil mixture containing high lauric acid natural oil (palm oil and rapeseed oil). Note the composition is essentially free of other antibiotics.

Page 3

The instant invention differs from the cited reference in that cited reference does not teach the instant composition is an antibacterial composition. However, the secondary reference, Isaacs et al., teaches fatty acids, including lauric acid, possess antibacterial activity. Clearly, one skilled in the art would have assumed the high lauric acid natural oil would posses the same antibacterial activity and lauric acid in that absence of evidence to the contrary. Note applicant's instant composition intended use does not distinguish the teachings of the Ohzeki et al. Applicant is reminded of the findings of In re Spada 15 USPQ2d 1655 (CAFC, 1990): "Discovery of new property or use of previously known composition, even if unobvious from prior art, cannot impart patentability to claims to known composition."

The instant invention differs from the cited references in that the cited references do not teach the weight percentage of the anti-bacterial fatty acid component of claims 12, 38 and 45. However, the determination of a weight percentage having optimum therapeutic index is well within the level of one having ordinary skill in the art, and the artisan would have been motivated to determine an optimum percentage to get the maximum effect of the composition.

Claims 10-12, 18, 38 and 45 are not allowed.

Art Unit: 1614

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 15-17, 25 and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Windholz et al., THE MERCK INDEX, Tenth Edition, 1983, page 893, abstract no. 6100 in view of Isaacs et al. (5,434,182).

Windholz et al. teach monesin as a well-known antibiotic used in the animal feed of chickens. Note monesin would be effective to against Salmonella typhimurium, a bacteria, in the absence of evidence to the contrary.

The instant invention differs from the cited reference in that the cited reference does not teach the addition of an antibacterial fatty acid as set forth in claims 25 and 26. However, the secondary reference, Isaacs et al., teaches antibacterial fatty acids. Clearly, one skilled in the art would have assumed to combination of two antibacterial agents into a single composition would give an additive effect in the absence of evidence to the contrary.

Claims 15-17, 25 and 26 are not allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kevin E. Weddington whose telephone number is (571)272-0587. The examiner can normally be reached on 11:00 am-7:30 pm.

Application/Control Number: 09/720,136 Page 5

Art Unit: 1614

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (571)272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kevin E. Weddington Primary Examiner Art Unit 1614

K. Weddington November 8, 2005